Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $103.70 USD
Change Today -1.51 / -1.44%
Volume 9.7M
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

333 Lakeside Drive

Foster City, CA 94404

United States

Phone: 650-574-3000

Fax: 650-578-9264

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company’s primary areas of focus include human immunodeficiency virus (HIV); liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection; oncology and inflammation; and serious cardiovascular and respiratory conditions. It has operations in approximately 30 countries worldwide. In the liver diseases area, the company received approval from the U.S. Food and Drug Administration (FDA) and the European Commission of Harvoni, the first once-daily single tablet regimen for the treatment of HCV genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, which was approved under the tradename Sovaldi in 2013. The company is evaluating tenofovir alafenamide (TAF) for the treatment of HBV and has completed the enrollment of Phase 3 clinical trials. The company is also conducting Phase 2 clinical studies of GS-4774, a Tarmogen T cell immunity stimulator; and GS-9620, an oral TLR-7 agonist, being evaluated as a potential cure for HBV. The company is evaluating simtuzumab for nonalcoholic steatohepatitis (NASH) in Phase 2 clinical trials. In December 2014, it also entered into an agreement with Phenex Pharmaceuticals AG (Phenex) under which the company acquired Phenex’s Farnesoid X Receptor (FXR) program consisted of small molecule FXR agonists for the treatment of liver diseases, including NASH. In the HIV area, the company submitted a new drug application for a once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and TAF 10 mg (E/C/F/TAF) for the treatment of HIV-1 infection in adults. The company also received approval in the United States of Tybost (cobicistat) and Vitekta (elvitegravir 85 mg and 150 mg), each a component of Stribild. The company also advanced its research and development pipeline, with 225 active clinical studies in 2014, of which approximately 54 were Phase 3 clinical trials. In December 2014, the company entered into an exclusive license agreement with ONO Pharmaceutical Co., Ltd. for the development and commercialization of GS-4059, an oral Bruton’s tyrosine kinase inhibitor for the treatment of B-cell malignancies and other diseases. Products HIV Stribild is an oral formulation dosed once a day for the treatment of HIV-1 infection in treatment-naive adults. Stribild is the company’s third complete single tablet regimen for the treatment of HIV and is a fixed-dose combination of its antiretroviral medications, Vitekta, Tybost, Viread, and Emtriva (emtricitabine). Stribild is approved by the FDA and the European Commission. Complera/Eviplera is an oral formulation dosed once a day for the treatment of HIV-1 infection in adults. The product, marketed in the United States as Complera and in Europe as Eviplera, is the company’s second complete single tablet regimen for the treatment of HIV and is a fixed-dose combination of its antiretroviral medications, Viread and Emtriva, and Janssen's non-nucleoside reverse transcriptase inhibitor, Edurant (rilpivirine). Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Atripla is the company’s first single tablet regimen for HIV intended as a therapy or in combination with other antiretrovirals. It is a fixed-dose combination of the company’s antiretroviral medications, Viread and Emtriva, and Bristol-Myers Squibb Company's non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz). Truvada (emtricitabine and tenofovir disoproxil fumarate) is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of the company’s antiretroviral medications, Viread and Emtriva. The FDA also approved Truvada, in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk, a strategy called pre-exposure prophylaxis. Viread is an o

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $103.70 USD -1.51

GILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.07 USD +1.82
Amgen Inc $167.91 USD -1.26
AstraZeneca PLC 4,750 GBp -80.50
Medtronic PLC $77.61 USD -0.89
Merck & Co Inc $57.60 USD +0.09
View Industry Companies
 

Industry Analysis

GILD

Industry Average

Valuation GILD Industry Range
Price/Earnings 14.3x
Price/Sales 6.4x
Price/Book 10.2x
Price/Cash Flow 12.9x
TEV/Sales 5.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.